Madrigal PharmaceuticalsRegister for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
| Period | Asset | Printed status |
|---|---|---|
| Q1 2026 | MGL-2086 (oral GLP-1) | Phase 1 on track to initiate in Q2 2026 |
| Q1 2026 | PNPLA3 siRNA | Clinical-stage license; $54.3 million upfront BD expense in the quarter |
| Period | Market | Printed status |
|---|---|---|
| Q2 2026 | Germany | Commercial launch underway |
| Q2 2026 | France | Early access program |
| Q2 2026 | United Kingdom | Approved |
| Q2 2026 | Europe contribution | Negligible in the quarter; expected negligible for FY 2026 |
| Period | Quarterly net sales ($M) | TTM net sales ($B, printed floor) |
|---|---|---|
| Q1 2026 | 311.3 | 1.1 |
| Q2 2026 | 364.3 | 1.3 |